Action VSTM VERASTEM, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Verastem, Inc.

Actions

VSTM

US92337C2035

Temps réel estimé Cboe BZX
Autres places de cotation
 16:33:40 28/06/2024 		Varia. 5j. Varia. 1 janv.
2,825 USD -2,59 % Graphique intraday de Verastem, Inc. -8,70 % -64,56 %
28/05 VERASTEM, INC. : RBC Capital Markets optimiste sur le dossier ZM
24/05 Les plus fortes baisses de la mi-journée MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
PR
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
PR
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
PR
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
BU
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
BU
Verastem: Q1 Earnings Snapshot
AQ
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
BU
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
BU
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
BU
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
BU
Verastem: Q4 Earnings Snapshot
AQ
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
BU
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
BU
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BU
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
BU
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VSTM
  4. Actualités Verastem, Inc.
  5. Communiqués